International Clinical Trial: A Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of YMN-A02, a Bifunctional RNA Agent, in Patients with Advanced Primary Hepatocellular Carcinoma Refractory to Standard Therapy

Geneva, May 7 -- International Clinical Trials Registry received information related to the study (ChiCTR2600123932) titled 'A Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of YMN-A02, a Bifunctional RNA Agent, in Patients with Advanced Primary Hepatocellular Carcinoma Refractory to Standard Therapy' on May 1.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: West China Hospital, Sichuan University

Condition: Primary Hepatocellular Carcinoma

Intervention: YMN-A02 100 µg Group:Enrolled subjects will receive a 100 µg intravenous infusion according to their assigned dose group. The dosing regimen includes 5 doses of primary immunization followed by subsequent individual...